How it works
A better way to treat obstructive sleep apnea.
StimAire is developing a rice-grain-sized device that will be implanted via a simple injection under local anesthesia.
Early Wins, Exciting Traction
Committed to expanding treatment access for patients
StimAire is rapidly moving toward product launch with FDA Breakthrough Device Designation. This designation is a formal identification by the U.S. FDA that a “medical device in development should be expedited for patient access because it has a reasonable chance of providing more effective treatment than the standard of care for life-threatening or irreversibly debilitating diseases or conditions“.
2020: Venture capital raised
.
2021: Patents issued
.
2023: Human sleep study results
.
2024: FDA Breakthrough Designation
.
2025: 100% On-target injections in animals.
2025: Six months chronic performance in animals
.
TBD: Pre-pivotal Clinical Trial
.
TBD: Pivotal Clinical Trial
.
TBD: FDA Market Approval
.
About us
Committed to minimizing the burden of obstructive sleep apnea
StimAire is led by seasoned MDs, researchers, and engineers specializing in sleep, neuromodulation, respiratory and ENT care.
We’re passionate about doing more for patients. This passion drove us to create a superior alternative treatment for obstructive sleep apnea.
Our mission is to bring the very best that modern technology can offer for the benefit of patients and physicians. Our first offering will be for the treatment of obstructive sleep apnea. You can find publications about us at these links:
https://www.linkedin.com/pulse/memo-stimaire-re-imagining-sleep-apnea-therapy-rhbwc/
https://www.sciencedirect.com/science/article/abs/pii/S1094715924012650
News & Resources
Get the latest updates and information StimAire, sleep apnea information and more.
